Nature Medicine Study: GLP-1 Therapy Shows Cardiovascular and Renal Benefits in Type 1 Diabetes
A major study published in Nature Medicine reveals that GLP-1 receptor agonist drugs, known for blood sugar control and weight loss, are also associated with a significantly reduced risk of major adverse cardiovascular events and kidney complications in patients with type 1 diabetes. This finding offers a new therapeutic perspective for managing type 1 diabetes.